European Journal of Clinical Pharmacology

, Volume 26, Issue 1, pp 113–119 | Cite as

Pharmacokinetics of estramustine phosphate (Estracyt®) in prostatic cancer patients

  • P. O. Gunnarsson
  • S. -B. Andersson
  • S. -Å. Johansson
  • T. Nilsson
  • G. Plym-Forshell


The pharmacokinetics of estramustine phosphate (EMP) was studied in five prostatic cancer patients given single i.v. and oral doses of EMP in a cross-over study. Plasma and urinary concentrations of parent drug, estramustine, estromustine (the estrone analogue), estradiol and estrone were followed for 32 h. The elimination of intravenous EMP from plasma was biphasic. The mean volumes of distribution were small, being 43 and 108 ml/kg for the central and peripheral compartments, respectively. The plasma clearance was 64 ml/kg/h, and the half-lives of the two phases were 0.16 and 1.27 h. Metabolism was the major route of elimination of EMP. It was readily dephosphorylated and oxidized to yield the cytotoxic metabolites estramustine and estromustine. Estromustine was the main metabolite in plasma. When given orally EMP underwent extensive presystemic dephosphorylation, which started in the gastrointestinal tract. The relative bioavailability of estromustine after administration of EMP-capsules was 44%, which reflects incomplete absorption of EMP rather than first-pass metabolism of estromustine. The terminal half-life of estromustine was 10–20 h, which suggests that EMP might be given once or twice a day.

Key words

estramustine phosphate prostatic cancer pharmacokinetics metabolism estramustine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jönsson G, Högberg B (1971) Treatment of advanced prostatic carcinoma with Estracyt. Scand J Urol Nephrol 5: 103–107Google Scholar
  2. 2.
    Mittelman A, Shukla SK, Murphy GP (1976) Extended therapy of stage D carcinoma of the prostate with oral Estracyt. J Urol 115: 409–412Google Scholar
  3. 3.
    Jönsson G, Högberg B, Nilsson T (1977) Treatment of advanced prostatic carcinoma with estramustine phosphate (Estracyt®). Scand J Urol Nephrol 11: 231–238Google Scholar
  4. 4.
    Andersson L, Edsmyr F, Jönsson G, Könyves I (1977) Estramustine phosphate therapy in carcinoma of the prostate. Recent Results Cancer Res 60: 73–77Google Scholar
  5. 5.
    Nagel R, Kölln C-P (1977) Treatment of advanced carcinoma of the prostate with Estracyt. Br J Urol 49: 73–79Google Scholar
  6. 6.
    Andersson S-B, Lundgren R, Svensson L (1982) Gas chromatographic determination of four metabolites of estramustine phosphate in plasma. Acta Pharm Suec 19: 1–10Google Scholar
  7. 7.
    Brooks MA, Dixon R (1980) Determination of estramustine and its 17-keto metabolite in plasma by high performance liquid chromatography. J Chromatogr 182: 387–394Google Scholar
  8. 8.
    Andersson S-B, Gunnarsson PO, Nilsson T, Plym Forshell G (1981) Metabolism of estramustine phosphate (Estracyt®) in patients with prostatic carcinoma. Eur J Drug Metab Pharmacokinet 6: 149–154Google Scholar
  9. 9.
    Dixon R, Brooks M, Gill G (1980) Estramustine phosphate: Plasma concentrations of its metabolites following oral administration to man, rat and dog. Res Commun Chem Pathol Pharmacol 27: 17–29Google Scholar
  10. 10.
    Forsgren B, Gunnarsson PO, Johansson S-Å, Kant R (1978) Radioimmunoassay of estramustine phosphate in plasma. Acta Pharm Suec 15: 200–210Google Scholar
  11. 11.
    Gunnarsson PO, Andersson S-B, Johansson S-Å (1984) In vitro studies on the metabolism of estramustine phosphate (Estracyt®). Eur J Drug Metab Pharmacokinet (in press)Google Scholar
  12. 12.
    Rowland M, Tucker G (1980) Symbols in pharmacokinetics. J Pharmacokinet Biopharm 8: 497–507Google Scholar
  13. 13.
    Rowland M, Tozer TN (1980) Clinical pharmacokinetics: Concepts and application. Lea & Febiger, Philadelphia, pp 1–331Google Scholar
  14. 14.
    Metzler CM, Elfring GL, McEwen AJ (1974) A package of computer programs for pharmacokinetic modeling. Biometrics 30: 562–572Google Scholar
  15. 15.
    Gunnarsson PO, Plym Forshell G, Fritjofsson Å, Norlén BJ (1981) Plasma concentrations of estramustine phosphate and its major metabolites in patients with prostatic carcinoma treated with different doses of estramustine phosphate (Estracyt®). Scand J Urol Nephrol 15: 201–206Google Scholar
  16. 16.
    Heel RG, Avery GS (1980) Drug data information. In: Avery GS (ed) Drug treatment, principles and practice of clinical pharmacology and therapeutics. 2nd ed. Adis Press, Sydney New York, pp 1211–1222Google Scholar
  17. 17.
    Plym Forshell G, Müntzing J, Ek A, Lindstedt E, Dencker H (1976) The absorption, metabolism and excretion of Estracyt in patients with prostatic cancer. Invest Urol 14: 128–131Google Scholar
  18. 18.
    Kirdani RY, Mittelman A, Murphy GP, Sandberg AA (1975) Studies on phenolic steroids in human subjects. XIV. Fate of a nitrogen mustard of estradiol-17β. J Clin Endocrinol Metab 41: 305–318Google Scholar
  19. 19.
    Balant LP, McAinsh J (1980) Use of metabolite data in the evaluation of pharmacokinetics and drug action. In: Jenner P, Testa B (eds) Concepts in drug metabolism, Part A, Vol. 10. Marcel Dekker, New York Basel, pp 311–371Google Scholar
  20. 20.
    Björk P, Forsgren B, Gustafsson J-Å, Pousette Å, Högberg B (1982) Partial characterization and “quantitation” of a human prostatic estramustine-binding protein. Cancer Res 42: 1935–1942Google Scholar
  21. 21.
    Leistenschneider W, Nagel R (1980) Estracyt therapy of advanced prostatic cancer with special reference to control of therapy with cytology and DNA cytophotometry. Eur Urol 6: 111–115Google Scholar
  22. 22.
    Hartley-Asp B, Gunnarsson PO (1982) Growth and cell survival following treatment with estramustine, nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU 145). J Urol 127: 818–822Google Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • P. O. Gunnarsson
    • 1
  • S. -B. Andersson
    • 1
  • S. -Å. Johansson
    • 1
  • T. Nilsson
    • 2
  • G. Plym-Forshell
    • 1
  1. 1.AB Leo, Research LaboratoriesCentral HospitalHelsingborgSweden
  2. 2.Department of UrologyCentral HospitalHelsingborgSweden

Personalised recommendations